{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-039286","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.626861+00:00","generated_at":"2026-06-04T04:30:59.728551+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024","bullets":["Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.","Operating expenses $31.4M in 2023, up $3.7M from $27.7M in 2022.","Phase 2 Karisma-Endoxifen (breast density) fully enrolled Nov 2023; top-line data expected H2 2024.","Phase 2 I-SPY 2 (neoadjuvant breast cancer) fully enrolled Feb 2024; data expected H2 2024.","First patient dosed in Phase 2 RECAST DCIS study; EVANGELINE data at AACR April 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-039286","json":"https://secwatch.observer/filing/0000950170-24-039286.json","markdown":"https://secwatch.observer/filing/0000950170-24-039286.md","text":"https://secwatch.observer/filing/0000950170-24-039286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/0000950170-24-039286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/atos-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:30:59.728551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e679ca418e156f99cf04f64cb4163ad2fc134112","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/0000950170-24-039286-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}